About This Page
This is a clinician-written, evidence-based guide aligned to the MCC Examination Objectives. It is structured by clinical presentation — the way the MCCQE tests and the way patients actually present. Management reflects current Canadian guidelines (CMA, CFPC, CPS). Always cross-reference with institutional protocols and clinical judgment.
The Bottom Line
- Menopause is usually a clinical diagnosis after 12 months of amenorrhea at the expected age.
- Perimenopause can cause irregular bleeding, but heavy, persistent, intermenstrual, or postmenopausal bleeding requires evaluation.
- Menopausal hormone therapy is most effective for vasomotor symptoms in appropriate candidates.
- Genitourinary syndrome of menopause is treated with lubricants/moisturizers and local vaginal estrogen or alternatives when appropriate.
- Primary ovarian insufficiency before 40 warrants evaluation and usually hormone therapy unless contraindicated.
Approach to the Presentation
Validate symptoms, exclude pregnancy and pathology when indicated, identify contraindications to hormone therapy, and counsel on benefits and risks. The key safety trap is postmenopausal bleeding, which always requires evaluation.
Differential Diagnosis
| diagnosis | likelihood | key features | distinguishing test |
|---|---|---|---|
| Endometrial Cancer or Hyperplasia | must-not-miss | Postmenopausal bleeding, persistent intermenstrual bleeding, obesity, diabetes, PCOS, tamoxifen, Lynch syndrome. | Endometrial biopsy; ultrasound may triage. |
| Pregnancy in Perimenopause | must-not-miss | Irregular cycles, missed periods, contraception stopped too early, nausea/breast tenderness. | Pregnancy test. |
| Primary Ovarian Insufficiency | must-not-miss | Amenorrhea/vasomotor symptoms before 40, infertility, autoimmune disease, chemotherapy. | Repeat elevated FSH with low estradiol. |
| Breast Cancer or Estrogen-Dependent Cancer Risk | must-not-miss | History of breast cancer, unexplained breast lump, abnormal mammogram. | Breast assessment/imaging/oncology input before systemic hormone therapy. |
| Normal Perimenopause | common | Cycle variability, hot flashes, night sweats, sleep disruption, mood changes. | Clinical diagnosis. |
| Genitourinary Syndrome of Menopause | common | Vaginal dryness, burning, dyspareunia, urinary symptoms, postcoital spotting. | Clinical examination. |
| Thyroid Disease | common | Heat intolerance, palpitations, weight change, tremor or cold intolerance. | TSH when atypical. |
| Mood or Anxiety Disorder | common | Low mood, anhedonia, anxiety, panic, sleep disturbance. | Clinical assessment, PHQ-9/GAD-7 as adjuncts. |
| Medication/Substance Effect | less common | SSRIs/SNRIs, opioids, anti-estrogen therapy, alcohol, cannabis. | Medication/substance review. |
| Vulvar Dermatosis or Infection | less common | Vulvar itch, discharge, fissures, lichen sclerosus changes. | Examination, swabs, biopsy if suspicious. |
Red Flags & Key History
Symptoms
Haemodynamic instability, syncope, severe pain, fever, or altered mental status — urgent assessment required.
Pregnancy possibility, positive pregnancy test, or pregnancy-related symptoms must change the diagnostic pathway.
Persistent, recurrent, or unexplained symptoms despite initial management require reassessment.
Cancer red flags such as postcoital/postmenopausal bleeding, mass, weight loss, or persistent abnormal discharge require diagnostic evaluation.
Patient priorities, fertility goals, contraception needs, trauma history, and psychosocial impact are central to management.
Medication, device, postpartum, lactation, and STI risk history often explains the presentation.
Signs
Abnormal vital signs, shock, sepsis, peritonism, hypoxia, severe hypertension, or neurological features.
Mass, cervical lesion, adnexal tenderness/mass, uterine tenderness, or abnormal bleeding on examination.
Fever, purulent discharge, cervical motion tenderness, wound infection, or breast erythema/fluctuance when relevant.
Normal examination does not exclude early pregnancy complications, endometriosis, intermittent torsion, or paroxysmal symptoms.
Document chaperone use, consent, and patient comfort for intimate examinations.
Approach to Investigation
First-line
Pregnancy test when pregnancy is possibleMandatory for reproductive-age presentations where bleeding, pain, amenorrhea, contraception failure, or procedure planning is relevant.
Focused history and examinationUse a trauma-informed approach; perform pelvic, breast, abdominal, or postpartum examination only when clinically indicated and consented.
CBC and targeted basic labsAssess anaemia, infection, platelets, renal/liver involvement, or endocrine clues depending on presentation.
Targeted microbiology or imagingUse STI NAAT, urinalysis, transvaginal ultrasound, breast imaging, fetal monitoring, or cervical testing according to the presentation.
Second-line
Ultrasound or diagnostic imagingPelvic, obstetric, breast, renal, or abdominal imaging according to the suspected diagnosis and pregnancy status.
Endocrine or tumour-directed testingUse TSH, prolactin, FSH/estradiol, androgen testing, CA-125, or biopsy only when the clinical pattern supports it.
Tissue diagnosis or samplingEndometrial biopsy, cervical biopsy/colposcopy, breast core biopsy, or hysteroscopy when malignancy, hyperplasia, or discordant findings are suspected.
Specialist
Gynecology/obstetric referralFor emergency, pregnancy-related, surgical, malignant, refractory, fertility-related, or complex presentations.
Multidisciplinary referralUse fertility, oncology, breast clinic, psychiatry, endocrinology, urology, pediatrics/neonatal, or social supports when indicated.
Management Principles
SOGC / Canadian specialty guidance + MCCQE1 clinical presentation approach1
Stabilize and exclude emergencies
- Assess ABCs, vital signs, pregnancy status, bleeding severity, sepsis, severe pain, severe hypertension, fetal status, and psychiatric safety as relevant.
- Call obstetrics/gynecology, anesthesia, blood bank, neonatal, psychiatry, surgery, or oncology early when red flags exist.
- Provide analgesia, antiemetics, fluids, antibiotics, antihypertensives, magnesium sulphate, or blood products when clinically indicated.
2
Treat according to most likely cause
- Use Canadian/SOGC/PHAC/Cancer Care Ontario-aligned pathways rather than non-Canadian defaults.
- Match management to patient goals: fertility, contraception, pregnancy continuation, breastfeeding, sexual function, symptom relief, and cancer risk.
- Do not delay empiric treatment for PID, obstetric emergency management, sepsis care, or psychiatric safety planning while waiting for confirmatory tests.
3
Shared decision-making and follow-up
- Explain uncertainty, expected course, treatment options, and return precautions in plain language.
- Arrange reliable follow-up for serial beta-hCG, repeat imaging, biopsy results, colposcopy, mental health review, or specialist assessment.
- Address equity, confidentiality, trauma history, intimate partner violence, cost, geography, and access barriers.
Complications & Pitfalls
- Skipping pregnancy testing: Many reproductive presentations change completely when pregnancy is present.
- Premature closure: Do not label symptoms as benign until must-not-miss causes have been considered.
- Ignoring red flags: Haemodynamic instability, sepsis, severe pain, psychosis, severe hypertension, or suspicious bleeding/mass require escalation.
- Overusing low-value care: Testing should be targeted; Pap tests, imaging, or hormone panels are not always required.
- Under-communicating follow-up: Serial testing, biopsy results, and safety-netting must be explicit.
MCCQE1 Exam Tips
- 1MCCQE1 reproductive questions are presentation-based: start with stability, pregnancy status, and must-not-miss diagnoses.
- 2The next best step is often the safest first step: beta-hCG, vital signs, focused examination, ultrasound, or urgent consultation depending on the vignette.
- 3Do not perform unsafe examinations or procedures before excluding key contraindications, such as digital vaginal examination before placenta previa is excluded.
- 4Canadian practice matters: use SOGC, PHAC STI guidance, Cancer Care Ontario pathways, and Choosing Wisely Canada principles where relevant.
- 5CanMEDS communicator role is common: consent, confidentiality, trauma-informed examination, shared decision-making, and sensitive counselling are testable.
- 6CanMEDS collaborator role is central in obstetric emergencies and cancer pathways: involve the right team early.
- 7Safety-netting is part of management: worsening pain, fever, heavy bleeding, syncope, fetal concerns, psychosis, or delayed follow-up require urgent reassessment.
practicetest your knowledge on menopause & perimenopausal symptomsApply what you've learnt with MCCQE1-style questions from the iatroX Q-Bank — reproductive & obstetric and beyond.
open q-bank